Advertisement

Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy

Published:January 07, 2023DOI:https://doi.org/10.1016/j.brachy.2022.12.002

      Abstract

      Purpose

      This study aims to evaluate the outcomes and toxicities in patients with palpable local recurrence of prostate cancer after radical prostatectomy (RP), who were treated with salvage high dose-rate brachytherapy (HDR-BT) with or without pelvic external beam radiotherapy (EBRT).

      Methods

      This retrospective review included patients with palpable local recurrence of prostate cancer after RP who underwent salvage HDR-BT at a single institution between 2002 and 2020. HDR-BT regimens included 950 cGy x 2 (N = 4) or 1500 cGy x 1 (N = 2) combined with EBRT; or monotherapy with 950 cGy x 4 (N = 1) or 800 cGy x 2 (N = 1). Toxicity was graded according to CTCAE Version 5.0.

      Results

      A total of 8 patients were included. Median follow-up was 49 months (range: 9–223 months). Median age at time of salvage brachytherapy was 68 years (range: 59–85 years). Seven out of 8 patients were alive at last follow-up. There have been no locoregional recurrences. Three patients developed distant metastatic disease. One patient developed acute grade 3 urinary obstruction requiring catheterization, which lasted for 1 day postbrachytherapy. One patient developed late grade 3 urinary incontinence 18 months after brachytherapy. There were no other grade 2+ toxicities.

      Conclusions

      This study demonstrates the safety and efficacy of salvage HDR-BT in the setting of palpable local recurrence of prostate cancer after RP, with durable locoregional control and acceptable rates of toxicity. HDR-BT should be further explored as an option for dose-escalated salvage radiotherapy after prior radical prostatectomy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Fuchs HE
        • et al.
        Cancer statistics.
        Cancer J Clin. 2021; 71 (2021): 7-33https://doi.org/10.3322/caac.21654
        • Thompson IM
        • Valicenti RK
        • Albertsen P
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline.
        J Urol. 2013; 190: 441-449https://doi.org/10.1016/j.juro.2013.05.032
        • Pound CR
        • Partin AW
        • Eisenberger MA
        • et al.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597https://doi.org/10.1001/jama.281.17.1591
        • Lange PH
        • Ercole CJ
        • Lightner DJ
        • et al.
        The value of serum prostate specific antigen determinations before and after radical prostatectomy.
        J Urol. 1989; 141: 873-879https://doi.org/10.1016/S0022-5347(17)41037-8
        • Pisansky TM
        • Kozelsky TF
        • Myers RP
        • et al.
        Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
        J Urol. 2000; 163: 845-850https://doi.org/10.1016/S0022-5347(05)67817-2
        • Pisansky TM
        • Thompson IM
        • Valicenti RK
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline amendment 2018-2019.
        J Urol. 2019; 202: 533-538https://doi.org/10.1097/JU.0000000000000295
        • Pollack A
        • Karrison TG
        • Balogh AG
        • et al.
        The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
        Lancet. 2022; 399: 1886-1901https://doi.org/10.1016/S0140-6736(21)01790-6
        • Parzen JS
        • Ye H
        • Gustafson G
        • et al.
        Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
        Radiother Oncol. 2020; 147: 123-129https://doi.org/10.1016/j.radonc.2020.03.033
        • Matta R
        • Chapple CR
        • Fisch M
        • et al.
        Pelvic complications after prostate cancer radiation therapy and their management: An International Collaborative Narrative Review.
        Eur Urol. 2019; 75: 464-476https://doi.org/10.1016/j.eururo.2018.12.003
        • Grills IS
        • Martinez AA
        • Hollander M
        • et al.
        High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
        J Urol. 2004; 171: 1098-1104https://doi.org/10.1097/01.ju.0000113299.34404.22
        • Hauswald H
        • Kamrava MR
        • Fallon JM
        • et al.
        High-dose-rate monotherapy for localized prostate cancer: 10-year results.
        Int J Radiat Oncol*Biol*Phys. 2016; 94: 667-674https://doi.org/10.1016/j.ijrobp.2015.07.2290
        • Morton G
        • McGuffin M
        • Chung HT
        • et al.
        Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
        Radiother Oncol. 2020; 146: 90-96https://doi.org/10.1016/j.radonc.2020.02.009
        • Clinically Localized Prostate Cancer
        AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.
        Journal of Urology. Accessed. March 14, 2022; (|)
        • Sanda MG
        • Cadeddu JA
        • Kirkby E
        • et al.
        Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part II: recommended approaches and details of specific care options.
        J Urol. 2018; 199: 990-997https://doi.org/10.1016/j.juro.2018.01.002
        • Hoskin PJ
        • Rojas AM
        • Bownes PJ
        • et al.
        Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
        Radiother Oncol. 2012; 103: 217-222https://doi.org/10.1016/j.radonc.2012.01.007
        • Joseph D
        • Denham JW
        • Steigler A
        • et al.
        Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial.
        Int J Radiat Oncol Biol Phys. 2020; 106: 693-702https://doi.org/10.1016/j.ijrobp.2019.11.415
        • Hsu IC
        • Rodgers JP
        • Shinohara K
        • et al.
        Long-term results of NRG oncology/RTOG 0321: a phase II trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate.
        Int J Radiat Oncol*Biol*Phys. 2021; 110: 700-707https://doi.org/10.1016/j.ijrobp.2020.11.008
        • Buchser D
        • Gomez-Iturriaga A
        • Melcon JIR
        • et al.
        Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.
        J Contemp Brachyther. 2016; 8: 477-483https://doi.org/10.5114/jcb.2016.64441
        • Macdonald OK
        • Schild SE
        • Vora SA
        • et al.
        Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1530-1535https://doi.org/10.1016/j.ijrobp.2003.09.082
        • Strom TJ
        • Wilder RB
        • Fernandez DC
        • et al.
        High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy.
        Brachytherapy. 2014; 13: 123-127https://doi.org/10.1016/j.brachy.2013.09.008
        • Cookson MS
        • Aus G
        • Burnett AL
        • et al.
        Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes.
        J Urol. 2007; 177: 540-545https://doi.org/10.1016/j.juro.2006.10.097
        • Raleigh DR
        • Chang AJ
        • Tomlin B
        • et al.
        Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
        Brachytherapy. 2015; 14: 795-800https://doi.org/10.1016/j.brachy.2015.06.004
        • Xu MJ
        • Chen KS
        • Chang AJ
        • et al.
        Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience.
        Brachytherapy. 2019; 18: 470-476https://doi.org/10.1016/j.brachy.2019.03.002
        • Kneebone A
        • Fraser-Browne C
        • Duchesne GM
        • et al.
        Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
        Lancet Oncol. 2020; 21: 1331-1340https://doi.org/10.1016/S1470-2045(20)30456-3
        • Parker CC
        • Clarke NW
        • Cook AD
        • et al.
        Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
        Lancet. 2020; 0https://doi.org/10.1016/S0140-6736(20)31553-1
        • Sargos P
        • Chabaud S
        • Latorzeff I
        • et al.
        Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1341-1352https://doi.org/10.1016/S1470-2045(20)30454-X
        • Vale CL
        • Fisher D
        • Kneebone A
        • et al.
        Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
        Lancet. 2020; 396: 1422-1431https://doi.org/10.1016/S0140-6736(20)31952-8
        • Zaine H
        • Vandendorpe B
        • Bataille B
        • et al.
        Salvage radiotherapy for macroscopic local recurrence following radical prostatectomy.
        Front Oncol. 2021; 11669261https://doi.org/10.3389/fonc.2021.669261
        • Vogel MME
        • Dewes S
        • Sage EK
        • et al.
        Feasibility and outcome of PSMA-PET-based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer.
        Front Oncol. 2021; 11715020https://doi.org/10.3389/fonc.2021.715020
        • Niehoff P
        • Loch T
        • Nürnberg N
        • et al.
        Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy.
        Brachytherapy. 2005; 4: 141-145https://doi.org/10.1016/j.brachy.2004.12.004
        • Jani AB
        • Schreibmann E
        • Goyal S
        • et al.
        18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
        Lancet. 2021; 397: 1895-1904https://doi.org/10.1016/S0140-6736(21)00581-X
        • Fendler WP
        • Calais J
        • Eiber M
        • et al.
        Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial.
        JAMA Oncol. 2019; 5: 856-863https://doi.org/10.1001/jamaoncol.2019.0096
        • Boreta L
        • Gadzinski AJ
        • Wu SY
        • et al.
        Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy.
        Urology. 2019; 129: 165-171https://doi.org/10.1016/j.urology.2018.12.055
        • Stephenson AJ
        • Scardino PT
        • Kattan MW
        • et al.
        Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
        J Clin Oncol. 2007; 25: 2035-2041https://doi.org/10.1200/JCO.2006.08.9607
        • King CR.
        The timing of salvage radiotherapy after radical prostatectomy: a systematic review.
        Int J Radiat Oncol*Biol*Phys. 2012; 84: 104-111https://doi.org/10.1016/j.ijrobp.2011.10.069